Post by Curium Pharma

Curium, together with PeptiDream Inc. and PDRadiopharma Inc., has completed patient dosing in the registrational Phase 2 trial of 64Cu-PSMA-I&T, a PSMA-targeted PET imaging agent for prostate cancer.    “This milestone reflects our commitment to expanding access to innovative radiopharmaceuticals for patients with prostate cancer across Asia,” said Renaud. Dehareng, CEO of Curium Group.    Read full press release here: https://lnkd.in/eDrXw788 #Curium #ProstateCancer #Theranostics #PSMA #NuclearMedicine